Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Net Debt: $37,374M in Q3 2026, up 83.5% from a year earlier.
Latest, Q3 2026
37,374
Period ended Sep 30, 2026
Change on a year earlier
+83.5%
20,365 in Q3 2025
History
21 quarters
Since Q2 2021
Sources
21
Documents cited below
Where the Q3 2026 figure comes from
“|| Net debt at end of period | – 37 374 | – 21 947 | – 20 365”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Displays the absolute value of financial debt less cash, cash equivalents, marketable securities, and derivatives.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up net Debt
- Total Financial Debts46,349 · Q3 2026
- Total Liquidity8,975 · Q3 2026
- USD-Denominated Long-Term Debt (Form 20-F)–
- EUR-Denominated Long-Term Debt Converted to USD–
- CHF-Denominated Long-Term Debt Converted to USD–
- Long-Term Debt in Other Currencies–
- Long-Term Debt Due within 1 Year–
- Long-Term Debt Due in 1–2 Years–
- Long-Term Debt Due in 2–3 Years–
- Long-Term Debt Due in 3–4 Years–
- Long-Term Debt Due in 4–5 Years–
- Long-Term Debt Due after 5 Years–
Cite this data
StockData. (2026). Novartis Net Debt ($M), quarterly Q2 2021–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/nd-net-debt
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.